# Giovanni Scambia

Source: https://onco.cc/people/giovanni-scambia/  
OnCo record `giovanni-scambia` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Giovanni Scambia is a gynaecologic oncologist who leads research at the Gemelli hospital.

## Summary

Giovanni Scambia is Scientific Director of the Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome and Professor of Gynaecology. His specialisms are gynaecological oncology, ovarian cancer surgery and cervical cancer, and he runs a large surgical and trial programme in ovarian, cervical and endometrial cancer. His papers include the SCORPION randomised trial of primary debulking surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer, the New England Journal of Medicine report of maintenance olaparib in newly diagnosed advanced ovarian cancer, and the long-term follow-up of the SOLO1/GOG 3004 trial of maintenance olaparib in patients with a BRCA mutation. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Scientific Director, Fondazione Policlinico Universitario A. Gemelli IRCCS; Professor of Gynaecology
- Specialisms: Gynaecological oncology; Ovarian cancer surgery; Cervical cancer

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Scambia%20G%5BAuthor%5D%20ovarian

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- institutions: [European Society of Gynaecological Oncology](https://onco.cc/institutions/esgo/), [Policlinico Universitario A. Gemelli](https://onco.cc/institutions/gemelli/)
- journals: [International journal of gynecological cancer](https://onco.cc/journals/international-journal-of-gynecological-cancer/)
- key papers: [KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)](https://onco.cc/key-papers/paper-keynote-a18-os-lancet-2024/), [KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)](https://onco.cc/key-papers/paper-keynote-a18-pfs-lancet-2024/), [PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours](https://onco.cc/key-papers/paper-paola-1-nejm-2019/), [SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer](https://onco.cc/key-papers/paper-solo-1-nejm-2018/)

---
JSON: https://onco.cc/api/v1/entities/giovanni-scambia.json